1. Hyderabad-based Hetero has received the manufacturing and marketing approval for the investigational antiviral medicine ‘Remdesivir’ from the Drug Controller General of India (DCGI) for treatment of Covid-19. 2. The drug has been granted approval for the treatment of suspected or laboratory-confirmed cases of Covid-19 in adults and children, hospitalized with severe symptoms of the disease. 3. It will be marketed under the brand name Covifor and available in 100 mg vial (injectable), which has to be administered intravenously in a hospital setting. 4. As per the government guidelines, patients are recommended 5-6 doses who are hospitalized with severe symptoms of the disease.